{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:38:40Z","timestamp":1792874320682,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013119","name":"PharmaMar","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102198","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:26:27Z","timestamp":1789140387000},"page":"102198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience"],"prefix":"10.1016","volume":"67","author":[{"given":"Naroa","family":"Amondarain Amenabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmele","family":"Mujika Eizmendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gabirondo Amenabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Crespo Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Mu\u00f1agorri Quiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elide","family":"Guti\u00e9rrez San Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Garc\u00eda \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iera","family":"Arrondo Arizmendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Bengoa Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez Amorena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddi","family":"S\u00e1nchez Urrestarazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larraitz","family":"Ega\u00f1a Ota\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Churruca Galaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102198_bb0010","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.1016\/j.annonc.2020.08.967","article-title":"828P expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer","volume":"31","author":"Baert","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco-22-114","article-title":"Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis","volume":"12","author":"Batalini","year":"2023","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0020","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2147\/DDDT.S451223","article-title":"Focus on trabectedin in ovarian cancer: what do we still need to know?","volume":"18","author":"Boccia","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.gore.2026.102198_bb0025","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gore.2026.102198_bb0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/ijgc-2022-004149","article-title":"Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102198_bb0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6\u201312 months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.gore.2026.102198_bb0045","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1200\/jco.2014.32.15_suppl.5551","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): results from OVA-301 follow-up","volume":"32","author":"Colombo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41416-022-02108-7","volume":"128","author":"Colombo","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gore.2026.102198_bb0055","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdq353","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval","volume":"22","author":"Kaye","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN guidelines\u00ae insights: ovarian Cancer\/fallopian tube Cancer\/primary peritoneal Cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Liu","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.gore.2026.102198_bb0075","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1200\/EDBK_238755","article-title":"Wanna get away? Maintenance treatments and chemotherapy holidays in gynecologic cancers","author":"Madariaga","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.gore.2026.102198_bb0080","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian Cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.gore.2026.102198_bb0090","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ejca.2012.04.001","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis","volume":"48","author":"Monk","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2026.102198_bb0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2019.12.043","article-title":"A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer","volume":"156","author":"Monk","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0100","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s12094-024-03531-3","article-title":"SEOM\u2013GEICO clinical guideline on epithelial ovarian cancer (2023)","volume":"26","author":"Perez-Fidalgo","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0105","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1002\/onco.13630","article-title":"A European, observational, prospective trial of Trabectedin plus Pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian Cancer","volume":"26","author":"Pignata","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2026.102198_bb0110","first-page":"23","article-title":"Impact of prior chemotherapy on outcomes with trabectedin\/pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"17","author":"Pignata","year":"2022","journal-title":"Cancer Chemother. Rev."},{"key":"10.1016\/j.gore.2026.102198_bb0115","article-title":"Introduction","volume":"19","author":"Pignata","year":"2025","journal-title":"Cancer Chemother. Rev."},{"key":"10.1016\/j.gore.2026.102198_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdq352","article-title":"Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6\u201312 months) subpopulation of OVA-301 phase III randomized trial","volume":"22","author":"Poveda","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fon-2017-0318","article-title":"Trabectedin mechanism of action and platinum resistance: molecular rationale","volume":"13","author":"Ray-Coquard","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0130","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e57","article-title":"Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus","volume":"34","author":"Redondo","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12885-024-12577-z","article-title":"Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study","volume":"24","author":"Rubio","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gore.2026.102198_bb0140","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00432-018-2637-1","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study","volume":"144","author":"Runnebaum","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0145","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.21873\/anticanres.14385","article-title":"GINECO prospective non-interventional PROSPECTYON study: Trabectedin plus Pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian Cancer","volume":"40","author":"Selle","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.gore.2026.102198_bb0150","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.gore.2026.102198_bb0155","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102198_bb0160","doi-asserted-by":"crossref","unstructured":"Vergote, I., Gonzalez-Martin, A., Lorusso, D., Gourley, C., Mirza, M.R., Kurtz, J.-E., Okamoto, A., Moore, K., Kridelka, F., McNeish, I., Reuss, A., Votan, B., Du Bois, A., Mahner, S., Ray-Coquard, I., Kohn, E.C., Berek, J.S., Tan, D.S.P., Colombo, N., Zang, R., Concin, N., O'Donnell, D., Rauh-Hain, A., Herrington, C.S., Marth, C., Poveda, A., Fujiwara, K., Stuart, G.C.E., Oza, A.M., Bookman, M.A., Mahner, S., Reuss, A., Du Bois, A., Grimm, C., Marth, C., Berger, R., Concin, N., Chang, T.-C., Ochiai, K., Gebski, V., Davis, A., Beale, P., Vergote, I., Kridelka, F., Denys, H., Vandecaveye, V., Candido Dos Reis, F.J., Del Pilar Estevez Diz, M., Stuart, G., MacKay, H., Carey, M., Cibula, D., Dundr (Path), P., Dorigo, O., Berek, J., O'Donnell, D., Saadeh, A., Boere, I., Lok, C., Coronado, P., Ottevanger, N., Tan, D.S., Ng, J., Gonzalez Martin, A., Oaknin, A., Poveda, A., Perez Fidalgo, A., Rauh-Hain, A., Lu, K., L\u00f3pez-Zavala, C., G\u00f3mez-Garc\u00eda, E.M., Ray-Coquard, I., Paoletti, X., Kurtz, J.-E., Joly, F., Votan, B., Bookman, M., Moore, K., Arend, R., Fujiwara, K., Fujiwara, H., Hasegawa, K., Bruchim, I., Tsoref, D., Oda, K., Okamoto, A., Enomoto, T., Michel, D., Kim, H.-S., Lee, J.-Y., Mukhopadhyay, A., Katsaros, D., Colombo, N., Pignata, S., Lorusso, D., Scambia, G., Kohn, E., Lee, J.-M., McNeish, I., Nicum, S., Farrelly, L., Sehouli, J., Keller, M., Braicu, E., Bj\u00f8rge, L., Mirza, M.R., Auranen, A., Welch, S., Oza, A.M., Heinzelmann, V., Gourley, C., Roxburgh, P., Herrington, C.S., Glasspool, R., Zang, R., Zhu, J., 2022. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 23, e374\u2013e384. doi:https:\/\/doi.org\/10.1016\/S1470-2045(22)00139-5.","DOI":"10.1016\/S1470-2045(22)00139-5"},{"key":"10.1016\/j.gore.2026.102198_bb0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/ijgc-2022-003764","article-title":"Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case\u2013control study","volume":"33","author":"Vertechy","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2026.102198_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103694","article-title":"Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer","volume":"9","author":"Xu-Vuillard","year":"2024","journal-title":"ESMO Open"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:26:46Z","timestamp":1792873606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S2352578926001785"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102198","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102198"}}